Abstract
Thymidylate synthase (TYMS) is the main molecular target for fluoropyrimidine anticancer drugs, and its expression has been correlated with the number of repeats of a 28-bp sequence in the 5′-untranslated region of the TYMS gene and with the presence of a G → C single-nucleotide polymorphism in the second repeat of 3R alleles. Based on this double polymorphism, three main TYMS alleles have so far been identified: TYMS 2R, TYMS 3RC and TYMS 3RG. During genetic analysis of TYMS polymorphisms in 100 colorectal cancer patients, three patients revealed an unexpected 113-bp band after electrophoresis of the restriction fragment length polymorphism analysis. Subsequent sequencing revealed two 28-bp repeats in the 5′-untranslated region and the presence in both repeats of cytosine instead of guanine at the 12th nucleotide. This allele variant (TYMS 2RC) has not been previously described in man. All three patients were heterozygotes for TYMS 2RC and experienced grade 2–3 chemotherapy-related toxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Popat S, Matakidou A, Houlston RS . Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529–536.
Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7: 4096–4101.
Mandola MV, Stoehmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898–2904.
Kawakami K, Watanabe G . Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004–6007.
Graziano F, Kawakami K, Watanabe G, Ruzzo A, Humar B, Santini D et al. Association of thymidylate synthase polymorphism with gastric cancer susceptibility. Int J Cancer 2004; 112: 1010–1011.
Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, Catalano V et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005; 11: 3778–3783.
Marcuello E, Altes A, Del Rio E, Cesar A, Menoyo A, Baiget M . Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 112: 733–737.
O’Connel MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246–250.
Miller AB, Hoogstraten B, Staquet M, Winker A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
Horie N, Aiba H, Oguro K, Takeishi K . Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene of thymidylate synthase. Cell Struct Funct 1995; 20: 191–197.
Acknowledgements
The financial support by Lega Italiana per la Lotta Contro i Tumori, Sezione di Rovigo, is acknowledged. Given the public source of funding, no duality of interest is declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gusella, M., Bolzonella, C., Crepaldi, G. et al. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J 6, 421–424 (2006). https://doi.org/10.1038/sj.tpj.6500401
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500401
Keywords
This article is cited by
-
Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo
The Pharmacogenomics Journal (2011)
-
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil
Journal of Cancer Research and Clinical Oncology (2010)
-
The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis
Molecular Diagnosis & Therapy (2010)
-
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
British Journal of Cancer (2009)
-
Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
The Pharmacogenomics Journal (2008)